Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Triple negative breast cancer (TNBC) is an aggressive cancer subtype with limited targeted treatment options.
• The heterogeneity and aggressive nature of TNBC necessitate the development of novel therapeutic strategies.
• Chalcones, compounds with a specific chemical scaffold, have demonstrated significant biological activities relevant to cancer treatment.

Purpose of the Study:

• To review the therapeutic potential of chalcone derivatives in the management of triple negative breast cancer.
• To highlight chalcones as promising candidates for novel anti-TNBC drug development.
• To consolidate current understanding of chalcones' role in combating TNBC.

Main Methods:

• Literature review of studies investigating chalcones and their derivatives.
• Analysis of research on the biological activities of chalcones against cancer cell lines, specifically TNBC.
• Synthesis of information regarding the chemical structure and anticancer mechanisms of chalcones.

Main Results:

• Chalcone scaffolds exhibit diverse and potent anticancer activities against various cancer types.
• Specific chalcone derivatives have shown significant efficacy in preclinical models of TNBC.
• The unique chemical structure of chalcones contributes to their targeted action in cancer cells.

Conclusions:

• Chalcones represent a promising class of compounds for the development of new drugs against triple negative breast cancer.
• Further research into chalcone derivatives could lead to improved treatment options for TNBC patients.
• The therapeutic role of chalcones in TNBC management is significant and warrants continued investigation.